論文 - 金井　弥栄

Novel method for DNA methylation analysis using high‐performance liquid chromatography and its clinical application

T Yotani, Y Yamada, E Arai, Y Tian, M Gotoh, M Komiyama, H Fujimoto, ...

Cancer science 109 (5), 1690-1700 2018年

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532 2018年

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532 2018年

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532 2018年

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532 2018年

Feasibility of methylome analysis using small amounts of genomic DNA from formalin‐fixed paraffin‐embedded tissue

K Ohara, E Arai, Y Takahashi, Y Fukamachi, N Ito, AM Maeshima, ...

Pathology international 68 (11), 633-635 2018年

Feasibility of methylome analysis using small amounts of genomic DNA from formalin‐fixed paraffin‐embedded tissue

K Ohara, E Arai, Y Takahashi, Y Fukamachi, N Ito, AM Maeshima, ...

Pathology international 68 (11), 633-635 2018年

Feasibility of methylome analysis using small amounts of genomic DNA from formalin‐fixed paraffin‐embedded tissue

K Ohara, E Arai, Y Takahashi, Y Fukamachi, N Ito, AM Maeshima, ...

Pathology international 68 (11), 633-635 2018年

Epigenome mapping of human normal purified hepatocytes: personal epigenome variation and genome–epigenome correlation

E Arai, F Miura, Y Totoki, S Yamashita, Y Tian, M Gotoh, H Ojima, ...

Epigenomics 10 (7), 955-979 2018年

Epigenome mapping of human normal purified hepatocytes: personal epigenome variation and genome–epigenome correlation

E Arai, F Miura, Y Totoki, S Yamashita, Y Tian, M Gotoh, H Ojima, ...

Epigenomics 10 (7), 955-979 2018年

Epigenome mapping of human normal purified hepatocytes: personal epigenome variation and genome–epigenome correlation

E Arai, F Miura, Y Totoki, S Yamashita, Y Tian, M Gotoh, H Ojima, ...

Epigenomics 10 (7), 955-979 2018年

ADAM9 is over‐expressed in human ovarian clear cell carcinomas and suppresses cisplatin‐induced cell death

M Ueno, T Shiomi, S Mochizuki, M Chijiiwa, M Shimoda, Y Kanai, ...

Cancer science 109 (2), 471-482 2018年

ADAM9 is over‐expressed in human ovarian clear cell carcinomas and suppresses cisplatin‐induced cell death

M Ueno, T Shiomi, S Mochizuki, M Chijiiwa, M Shimoda, Y Kanai, ...

Cancer science 109 (2), 471-482 2018年

ADAM9 is over‐expressed in human ovarian clear cell carcinomas and suppresses cisplatin‐induced cell death

M Ueno, T Shiomi, S Mochizuki, M Chijiiwa, M Shimoda, Y Kanai, ...

Cancer science 109 (2), 471-482 2018年

511 IDENTIFICATION OF CYP2A6 GENE RELATED TO INVASIVE BLADDER CARCINOGENESIS

K Kanemoto, K Fukuta, K Yamada, N Kawai, K Tozawa, Y Kanai, ...

JOURNAL OF UROLOGY 200 (3), e208-e208 2018年

511 IDENTIFICATION OF CYP2A6 GENE RELATED TO INVASIVE BLADDER CARCINOGENESIS

K Kanemoto, K Fukuta, K Yamada, N Kawai, K Tozawa, Y Kanai, ...

JOURNAL OF UROLOGY 200 (3), e208-e208 2018年

511 IDENTIFICATION OF CYP2A6 GENE RELATED TO INVASIVE BLADDER CARCINOGENESIS

K Kanemoto, K Fukuta, K Yamada, N Kawai, K Tozawa, Y Kanai, ...

JOURNAL OF UROLOGY 200 (3), e208-e208 2018年

Hyaluronan binding protein involved in hyaluronan depolymerization(HYBID)はヒアルロン酸代謝を介して内軟骨性骨形成を制御する

下田 将之, 吉田 浩之, 水野 早希子, 弘實 透, 堀内 圭輔, 吉野 雄太, 原 英彰, 金井 弥栄, 井上 紳太郎, 石島 旨章, 岡田 保典

日本結合組織学会学術大会プログラム・抄録集 （日本結合組織学会）  49回   42 - 42 2017年06月

査読有り

長管骨形成に関わるHYBIDの役割解析

下田 将之, 吉田 浩之, 水野 早希子, 堀内 圭輔, 吉野 雄太, 原 英彰, 金井 弥栄, 井上 紳太郎, 石島 旨章, 岡田 保典

日本病理学会会誌 （(一社)日本病理学会）  106 （ 1 ） 307 - 307 2017年03月

査読有り,  ISSN  0300-9181

Liver atrophy after percutaneous transhepatic portal embolization occurs in two histological phases: Hepatocellular atrophy followed by apoptosis

金井 弥栄

World Journal of Hepatology （World Journal of Hepatology）  9 （ 32 ） 1227 - 1238 2017年

査読有り,  ISSN  1948-5182

　概要を見る

© The Author(s) 2017. AIM To clarify the histological changes associated with liver atrophy after percutaneous transhepatic portal embolization (PTPE) in pigs and humans. METHODS As a preliminary study, we performed pathological examinations of liver specimens from five pigs that had undergone PTPE in a time-dependent model of liver atrophy. In specimens from embolized lobes (EMB) and nonembolized lobes (controls), we measured the portal vein to central vein distance (PV-CV), the area and number of hepatocytes per lobule, and apoptotic activity using the terminal deoxynucleotidyl transferase dUTP nickend labeling assay. Immunohistochemical reactivities were evaluated for light chain 3 (LC3) and lysosomal-associated membrane protein 2 (LAMP2) as autophagy markers and for glutamine synthetase and cytochrome P450 2E1 (CYP2E1) as metabolic zonation markers. Samples from ten human livers taken 20-36 d after PTPE were similarly examined. RESULTS PV-CVs and lobule areas did not differ between EMB and controls at day 0, but were lower in EMB than in controls at weeks 2, 4, and 6 (P ≤ 0.001). Hepatocyte numbers were not significantly reduced in EMB at day 0 and week 2 but were reduced at weeks 4 and 6 (P ≤ 0.05). Apoptotic activity was higher in EMB than in controls at day 0 and week 4. LC3 and LAMP2 staining peaked in EMB at week 2, with no significant difference between EMB and controls at weeks 4 and 6. Glutamine synthetase and CYP2E1 zonation in EMB at weeks 2, 4, and 6 were narrower than those in controls. Human results were consistent with those of porcine specimens. CONCLUSION The mechanism of liver atrophy after PTPE has two histological phases: Hepatocellular atrophy is likely caused by autophagy in the first 2 wk and apoptosis thereafter.

• Access to Document (DOI)